Keywords
How to Cite
Abstract
Currently it is established that cancer is a genetic disease and that somatic mutations are the initiators of the carcinogenic process. The PI3K/AKT/mTOR pathway is an important intracellular signaling pathway regulating the cell growth and metabolic activities. Aberrant activation of the PI3K pathway is commonly observed in many different cancers. In this review we analyze the genetic alterations of PI3K pathway in a variety of human malignancies and discuss their possible implications for diagnosis and therapy.References
Abid M.R., Guo S., Minami T. et al. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells // Arterioscler Thromb Vasc Biol. - 2004. - Vol. 24. - P. 294-300.
Altiok S., Batt D., Altiok N. et al. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells // J. Biol. Chem. -1999. - Vol. 274. - P. 32274-32278.
Bagrodia S., Smeal T, Abraham R.T. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies // Pigment. Cell Melanoma Res. - 2012. - Vol. 25. - P. 819-831.
Bai H., Li H., Li W. et al. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines // oncotar-get. - 2015. - Vol. 6. - P. 25520-25532.
Banerjee S., Kaye S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential // Clin. Cancer Res. - 2013. - Vol. 19. - P. 961-968.
Cai J., Xu L., Tang H. et al. The role of the PTEN/PI3K/ Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis // Oncologist. - 2014. - Vol. 19. - P. 528-535.
Campbell I.G., Russell S.E., Choong D.YH. et al. Mutation of the PIK3CA gene in ovarian and breast cancer // Cancer Res. - 2004. - Vol. 64. - P. 7678-7681.
Campbell R.A., Bhat-Nakshatri P., Patel N.M. et al. Phos-phatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance // J. Biol. Chem. -2001. - Vol. 276. - P. 9817-9824.
Carden C.P., Stewart A., Thavasu P. et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer // Mol. Cancer Ther. - 2012. - Vol. 11. - P. 1609-1617.
Cecconi S., Ciccarelli C., Barberi M. et al. Granulosa cell-oocyte interactions // Eur. J. Obstet. Gynecol. Reprod. Biol. - 2004. - Vol. 115. Suppl. - P. S19-22.
Cecconi S., Mauro A., Cellini V. et al. The role of Akt signalling in the mammalian ovary // Int. J. Dev. Biol. - 2012. - Vol. 56. - P. 809-817.
Chandarlapaty S., Sawai A., Scaltriti M. et al. AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity //Cancer Cell. - 2011. - Vol. 19. - P. 58-71.
Chang Y-S., Hsu H.-T., Ko Y-C. et al. Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma // Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. - 2014. - Vol. 118. - P. 110-116.
Cheaib B., Auguste A., Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges // Chin. J. Cancer. - 2015. - Vol. 34. - P. 4-16.
Cheung L.W.T., Hennessy B.T., Li J. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability // Cancer Discov. - 2011. - Vol. 1. - P. 170-185.
Cizkova M., Vacher S., Meseure D. et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer // BMC Cancer. - 2013. - Vol. 13. - P. 545.
Coomans de Brach ne A., Demoulin J.-B. FOXO transcription factors in cancer development and therapy // Cell Mol. Life Sci. - 2016. - Vol. 73. - P. 1159-1172.
Cross M.J., Dixelius J., Matsumoto T. et al. VEGF-receptor signal transduction // Trends Biochem Sci. - 2003. - Vol. 28. - P. 488-494.
Datta S.R., Dudek H., Tao X. et al. Akt phosphorylation of BAD couples survival signals to the Cell-intrinsic death machinery // Cell. - 1997. - Vol. 91. - P. 231-241.
Dufour M., Dormond-Meuwly A., Pythoud C. et al. Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects // Biochem Biophys. Res. Commun. - 2013. - Vol. 438. - P. 32-37.
Ellis M.J., Lin L., Crowder R. et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer // Breast Cancer Res. Treat. - 2010. - Vol. 119. - P. 379-390.
Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. //Nat. Rev. Cancer. - 2009. - Vol. 9. - P. 550-562.
Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism // Nat. Rev. Genet. - 2006. - Vol. 7. - P. 606-619.
Faes S., Dormond O. PI3K and AKT: Unfaithful Partners in Cancer // Int. J. Mol. Sci. - 2015. -Vol. 16. - P. 21138-21152.
Fang X., Yu S., Eder A. et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway // Oncogene. - 1999. - Vol. 18. - P. 6635-6640.
Fernando R.I., Wimalasena J. Estradiol abrogates apop-tosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt // Mol. Biol. Cell. - 2004. - Vol. 15. - P. 3266-3284.
Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors // Nat. Med. - 2003. - Vol. 9. - P. 669-676.
Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases // Annu. Rev. Biochem. -1998. - Vol. 67. - P. 481-507.
Furet P., Guagnano V., Fairhurst R.A. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation // Bioorg. Med. Chem. Lett. - 2013. - Vol. 23. - P. 3741-3748.
Gonzalez-Angulo A.M., Chen H., Karuturi M.S. et al. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast Cancer. // Cancer. - 2013. - Vol. 119. - P. 7-15.
Greenhough A., Patsos H.A., Williams A.C. et al. The can-nabinoid A9-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells // Int. J. Cancer. - 2007. - Vol. 121. - P. 2172-2180.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. - 2011. - Vol. 144. - P. 646-674.
Hayes M.P., Wang H., Espinal-Witter R. et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia // Clin. Cancer Res. - 2006. - Vol. 12. - P. 5932-5935.
He Y, Van't Veer L.J., Mikolajewska-Hanclich I. et al. PIK-3CA mutations predict local recurrences in rectal cancer patients // Clin. Cancer Res. - 2009. - Vol. 15. - P. 6956-6962.
Hu L., Hofmann J., Lu Y et al. Inhibition of phosphati-dylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models // Cancer Res. - 2002. - Vol. 62. - P. 1087-1092.
Huang C.-H., Mandelker D., Schmidt-Kittler 0. et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations // Science. - 2007. - Vol. 318. - P. 1744-1748.
Huang J., Zhang L., Greshock J. et al. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome // Genes. Chromosomes. Cancer. - 2011. - Vol. 50. - P. 606-618.
Irie H.Y, Pearline R. V, Grueneberg D. et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition // J. Cell Biol. - 2005. - Vol. 171. - P. 1023-1034.
Isakoff S.J., Engelman J.A., Irie H.Y et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells // Cancer Res. - 2005. - Vol. 65. - P. 10992-11000.
Janku F., Tsimberidou A.M., Garrido-Laguna I. et al. PIK-3CA mutations in patients with advanced cancers treated with PI3K/AKT/mT0R axis inhibitors // Mol. Cancer Ther. - 2011. -Vol. 10. - P. 558-565.
Jiang B.H., Jiang G., Zheng J.Z. et al. Phosphatidylinosi-tol 3-kinase signaling controls levels of hypoxia-inducible factor 1 // Cell Growth Differ. - 2001. - Vol. 12. - P. 363-369.
Junttila T.T., Akita R.W., Parsons K. et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastu-zumab and is effectively inhibited by the PI3K inhibitor GDC-0941 // Cancer Cell. - 2009. - Vol. 15. - P. 429-440.
Kaur J., Sanyal S.N. PI3-kinase/Wnt association mediates C0X-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac // Tumor Biol. -2010. - Vol. 31.- P. 623-631.
Krasilnikov M.A. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation // Biochemistry (Mosc). - 2000. - Vol. 65. - P. 59-67.
Kristensen T.B., Knutsson M.L.T., Wehland M. et al. Anti-vascular endothelial growth factor therapy in breast cancer // Int. J. Mol. Sci. - 2014. - Vol. 15. - P. 2302423041.
Kuo K.-T, Mao T.-L., Jones S. et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma // Am. J. Pathol. - 2009. - Vol. 174. - P. 1597-1601.
Kushlinskii N.E., Gershtein E.S. Role of vascular endothelial growth factor during breast cancer // Bull. Exp. Biol. Med. - 2002. - Vol. 133. - P. 521-528.
Lai K., Killingsworth M.C., Lee C.S. Gene of the month: PIK3CA // J. Clin. Pathol. - 2015. - Vol. 68. - P. 253257.
Levine D.A., Bogomolniy F., Yee C.J. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers // Clin. Cancer Res. - 2005. - Vol. 11. - P. 2875-2878.
Liao X., Lochhead P., Nishihara R. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival // N. Engl. J. Med. - 2012. - Vol. 367. - P. 1596-1606.
Liu P., Cheng H., Roberts T.M. et al. Targeting the phosphoinositide 3-kinase pathway in cancer // Nat. Rev. Drug. Discov. - 2009. - Vol. 8. - P. 627-644.
Liu S., Knapp S., Ahmed A.A. The structural basis of PI3K cancer mutations: from mechanism to therapy // Cancer Res. - 2014. - Vol. 74. - P. 641-646.
Liu Y, Sun S.-Y, Owonikoko T.K. et al. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells // Mol. Cancer Ther. - 2012. - Vol. 11. - P. 45-56.
Lux M.P., Fasching P.A., Schrauder M.G. et al. The PI3K Pathway: Background and Treatment Approaches // Breast Care. - 2016. - Vol. 11. - P. 398-404.
Mao C., Yang Z.Y, Hu X.F. et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EG-FR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis // Ann. Oncol. - 2012. - Vol. 23. - P. 1518-1525.
Matkar S., Sharma P., Gao S. et al. An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis //Cancer Cell. - 2015. - Vol. 28. - P. 472-485.
Miled N., Yan Y, Hon W.-C. et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit //Science. - 2007. - Vol. 317. - P. 239-242.
Murugan A.K., Hong N.T., Fukui Y et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas // Int. J. Oncol. - 2008. - Vol. 32. - P. 101-111.
Di Nicolantonio F., Arena S., Tabernero J. et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus // J. Clin. Invest. - 2010. - Vol. 120. - P. 2858-2866.
O Farrell F., Rusten T.E., Stenmark H. Phosphoinositide 3-kinases as accelerators and brakes of autophagy // FEBS J. - 2013. - Vol. 280. - P. 6322-6337.
Obata K., Morland S.J., Watson R.H. et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors // Cancer Res. - 1998. - Vol. 58. - P. 2095-2097.
Paplomata E., O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers // Ther Adv. Med. Oncol. - 2014. - Vol. 6. - P. 154-166.
Philp A.J., Campbell I.G., Leet C. et al. The phos-phatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors // Cancer Res. - 2001. - Vol. 61. - P. 7426-7429.
Reagan-Shaw S. RNA Interference-Mediated Depletion of Phosphoinositide 3-Kinase Activates Forkhead Box Class O Transcription Factors and Induces Cell Cycle Arrest and Apoptosis in Breast Carcinoma Cells // Cancer Res. - 2006. - Vol. 66. - P. 1062-1069.
Robey R.B., Hay N. Is Akt the ‘Warburg kinase'?-Akt-en-ergy metabolism interactions and oncogenesis // Semin Cancer Biol. - 2009. - Vol. 19. - P. 25-31.
Saal L.H., Holm K., Maurer M. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma // Cancer Res. - 2005. - Vol. 65. - P. 2554-2559.
Samuels Y, Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers // Cell Cycle. -2004. - Vol. 3. - P. 1221-1224.
Samuels Y, Wang Z., Bardelli A. et al. High frequency of mutations of the PIK3CA gene in human cancers // Science. - 2004. - Vol. 304. - P. 554.
Scheijen B., Ngo H.T., Kang H., et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. // Oncogene. -2004.-Vol. 23- P.3338-49.
Scherbakov A.M., Sorokin D. V, Tatarskiy V. V, et al. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. //IUBMB Life. -2016.-Vol. 68- P. 281-92.
Serra V., Scaltriti M., Prudkin L., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. // Oncogene. -2011.-Vol. 30- P.2547-57.
Smit L., Berns K., Spence K., et al. An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation. //Oncotarget. -2016.-Vol. 7- P.2596-610.
Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. //J Cell Mol Med. -2005.-Vol. 9- P.59-71.
Stein R.C. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. //Endocr Relat Cancer. -2001.-Vol. 8- P.237-48.
Taniguchi C.M., Winnay J., Kondo T, et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. //Cancer Res. -2010.-Vol. 70- P.5305-15.
Tian W.-Y, Chen W.-C., Li R., et al. Markers CD40, VEGF, AKT, PI3K, and S100 correlate with tumor stage in gastric cancer. //Onkologie. -2013.-Vol. 36- P.26-31.
Velho S., Moutinho C., Cirnes L., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? //BMC Cancer. -2008.-Vol. 8- P.255.
Volinia S., Hiles I., Ormondroyd E., et al. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. //Genomics. -1994.-Vol. 24- P.472-7.
Wang L., Zhang Q., Zhang J., et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. //BMC Cancer. -2011.-Vol. 11- P.248.
Whitehall V.L.J., Rickman C., Bond C.E., et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. //Int J Cancer. -2012.-Vol. 131- P.813-20.
Whitman M., Kaplan D.R., Schaffhausen B., et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. //Nature. -1985.-Vol. 315- P.239-42.
Williams R.L., Walker E.H., Perisic O., et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. //Nature. -1999.-Vol. 402- P.313-20.
Wu G., Xing M., Mambo E., et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. //Breast Cancer Res. -2005.-Vol. 7- P.R609-16.
Young N.R., Liu J., Pierce C., et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. //Mol Oncol. -2013.-Vol. 7- P.359-68.
Yu F. Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. //Oncol Lett. -2013.
Yue W., Wang X., Wang Y [The Relationship between the PI3K/Akt/mTOR Signal Transduction Pathway and Nonsmall Cell Lung Cancer.]. //Zhongguo Fei Ai Za Zhi. -2009.-Vol. 12- P.312-5.
Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. //Oncogene. -2008.-Vol. 27- P.5486-96.
Zhong H., Chiles K., Feldser D., et al. Modulation of hy-poxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. //Cancer Res. -2000.-Vol. 60- P.1541-5.
Zhou X.D., Chen H.X., Guan R.N., et al. Protein kinase B phosphorylation correlates with vascular endothelial growth factor A and microvessel density in gastric adenocarcinoma. //J Int Med Res. -2012.-Vol. 40- P.2124-34.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017